Search clinical trials for: Comparator: erlotinib dalotuzumab

Total 3456 results

Merck Sharp & Dohme LLC

Completed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Carcinoma, Non-small Cell Lung
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Neoplasms
Clinical Nutrition Research Center, Illinois Institute...

Completed

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance (GSE3)

Impaired Glucose Tolerance

United States
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
Merck Sharp & Dohme LLC

Completed

A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)

Advanced Solid Tumors
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Merck Sharp & Dohme LLC

Completed

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Multiple Myeloma | Solid Tumor
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Neoplasm
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
University of Turku
Government Body Funding

Completed

Intestinal Microbiota: Immunity, Recovery and Metabolic Health (VAR-MIKRO)

Healthy

Finland
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Bristol-Myers Squibb
AbbVie

Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Abbott
Bristol-Myers Squibb

Terminated

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

United States
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic

United States
Duke University
Genentech, Inc.

Completed

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Glioblastoma | Gliosarcoma

United States
Merck Sharp & Dohme LLC

Completed

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Schizophrenia
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Multiple Myeloma

United States
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Eisai Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Breast Cancer
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Merck Sharp & Dohme LLC

Terminated

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Middle Cerebral Artery Stroke
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
TiumBio Co., Ltd.

Recruiting

TUC3PII-01_TU2670 Phase IIa Clinical Study

Endometriosis

Czechia, Italy, Russian Federation, Poland, Ukraine
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

China, Hong Kong, Taiwan, Philippines, Thailand, Korea, Republic of, Indonesia
Merck Sharp & Dohme LLC

Terminated

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Solid Tumors
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
M.D. Anderson Cancer Center

Completed

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Advanced Cancers

United States
Cognition Therapeutics

Recruiting

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Age-Related Macular Degeneration

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

Sarcopenia
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Completed

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Rotavirus
University of Chicago
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Malignant Peritoneal Mesothelioma

United States
United States Naval Medical Center, San Diego

Terminated

Low -vs- High-Frequency Repetitive TMS of the Right Dorsolateral Prefrontal Cortex in PTSD

PTSD - Post Traumatic Stress Disorder
Guangzhou JOYO Pharma Co., Ltd

Recruiting

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

China
AbbVie

Withdrawn

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Psoriasis
Clinical Nutrition Research Center, Illinois Institute...

Completed

Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study (COF1)

Healthy | Overweight | Obese

United States
Duke University
Bristol-Myers Squibb; Genentech, Inc.

Completed

Ph I Dasatinib + Erlotinib in Recurrent MG

Glioblastoma | Gliosarcoma

United States
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
New Mexico Cancer Care Alliance

Completed

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States

3

Subscribe